The evidence runs in the right direction and there is very little of it. Five studies, 182 participants, and an 8.14-point improvement in Binge Eating Scale scores against control [1]. The confidence interval runs from 13.13 points to 3.15, which is the distance between a substantial clinical change and a barely perceptible one.
A meaningful share of the people buying these drugs are not buying them for a number on a scale. They are buying them because eating feels different on them, and because the thing that was hardest to control appears to become controllable. That is a serious reason, and it deserves a straight account of how much evidence sits behind it. This site gives the same account of the weight claims in is a GLP-1 worth what it costs.
How much evidence there is
A 2025 systematic review and meta-analysis found five studies of GLP-1 agonists in binge eating disorder, pooling 182 participants in total [1]. That is the whole randomized literature, and it is roughly the size of a single phase 2 arm elsewhere in this field.
Across those studies, Binge Eating Scale scores improved by 8.14 points against control (95% CI 13.13 to 3.15). Weight fell by 3.81 kg more than control (95% CI 5.14 to 2.49), BMI by 1.48 kg/m² and waist circumference by 3.14 cm. Those weight figures are modest beside the trials collected in what a GLP-1 actually costs.
What users report, and why it reads high
The larger numbers in this area come from surveys rather than trials. A survey of 550 US adults on injectable semaglutide scored food preoccupation at a median of 6 out of 20 on treatment [2]. The median recalled for before starting was 13.
Nobody was asked before they started. People who believe a treatment worked reliably remember a worse starting point than they described at the time. So the baseline is the weak half of that comparison. The direction is probably real and the size is inflated by the design.
Attempts to match a drug to an eating pattern are thinner again. A São Paulo clinic scored 66 patients across five medications and reported standardized effect sizes above 2 for emotional and hedonic eating [3]. That is roughly a dozen patients per drug, and very large effect sizes are what small paired samples produce.
What the online market has to do with it
Nothing, formally, and that is the point. No storefront tracked on this site is licensed to treat an eating disorder, and none advertises that it does. An intake questionnaire is not a diagnostic instrument. A person buying a compounded vial because eating feels uncontrollable is buying a weight-loss product. They are hoping it does something the product was not sold to do.
That may still work. What it does not come with is anyone watching. Most sellers here publish nothing about who reviews a case, how often, or how to reach them. The silence counted in what nobody says about a higher dose applies to the clinical side as much as to the price.
The practical reading
The direction of the evidence is favorable and its quantity is small. If binge eating is the reason for interest, involve a clinician who can diagnose it and monitor what happens. That is not a reason to avoid the drug. It is also worth knowing what stopping does. The effect on eating is an on-treatment effect like every other one here, covered in what stopping costs and in two-thirds stop within a year.